Imigran Radis (Sumatriptan)

Sumatriptan is a selective 5‑HT1B/1D receptor agonist. By stimulating these serotonin receptors on cranial blood vessels, it causes vasoconstriction and blocks the release of pro‑inflammatory neuropeptides from trigeminal nerve endings, thereby reducing vascular dilation and pain signaling associated with migraine.

The dose of Imigran Radis is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and regulatory guidelines. Typical oral tablet strengths are 25 mg, 50 mg, or 100 mg, but the exact regimen must be individualized and written on the prescription.

Safety of sumatriptan in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult a healthcare professional before use. Clinical decisions are made on a case‑by‑case basis.

To place an order, submit an enquiry on the Imigran Radis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other triptans, sumatriptan has a rapid onset of action and is available in multiple oral strengths, making it suitable for early intervention. Non‑triptan options such as NSAIDs or gepants have different mechanisms and may be chosen when triptans are contraindicated or ineffective.

Imigran Radis tablets should be stored at below 25 °C in a dry place, protected from moisture and light. Keep the medication in its original packaging until use, and ensure it is out of reach of children. Do not store in bathrooms or near heat sources.

Imigran Radis is taken orally with a glass of water, preferably at the first sign of a migraine attack. The tablet can be swallowed whole; it should not be crushed or chewed. Patients should follow the dosing instructions provided by their prescriber and may repeat the dose after a minimum interval if needed.

Serious risks include coronary vasospasm, myocardial ischemia, and serotonin syndrome, especially when combined with other serotonergic agents. Patients with cardiovascular disease, uncontrolled hypertension, or a history of stroke should be evaluated carefully before use. Immediate medical attention is required if chest pain, severe allergic reaction, or signs of serotonin excess occur.

Imigran Radis is contraindicated in patients with known hypersensitivity to sumatriptan or any component of the formulation, in those with a history of ischemic heart disease, uncontrolled hypertension, peripheral vascular disease, or in individuals who have taken another triptan or ergot derivative within the previous 24 hours. Consultation with a healthcare professional is essential.